^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
arsenic trioxide oral (SY-2101)
i
Other names: SY-2101, ORH-2014
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Syros
Drug class:
DNA synthesis inhibitor
Related drugs:
6ms
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia (clinicaltrials.gov)
P1, N=16, Suspended, Syros Pharmaceuticals | N=24 --> 16 | Recruiting --> Suspended | Trial primary completion date: Apr 2024 --> Jan 2024
Enrollment change • Trial suspension • Trial primary completion date
|
Chr t(15;17) • Chr t(15;17)/PML-RARA fusion
|
arsenic trioxide oral (SY-2101)
1year
A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia (clinicaltrials.gov)
P1, N=24, Recruiting, Syros Pharmaceuticals | Trial completion date: Mar 2023 --> Apr 2024 | Trial primary completion date: Mar 2023 --> Apr 2024
Trial completion date • Trial primary completion date
|
Chr t(15;17) • Chr t(15;17)/PML-RARA fusion
|
arsenic trioxide oral (SY-2101)
Share via
